Starting Wegovy: Complete Dosing Guide for Beginners

If you were just prescribed Wegovy (semaglutide), the dosing schedule can look confusing at first glance. The short answer: Wegovy is started at a low dose and increased every four weeks over roughly four months until you reach your target maintenance dose. This step-up approach, called dose titration, is built into the FDA-approved prescribing information for Wegovy and is not something your prescriber is improvising. Understanding why it works this way, and what the actual schedule looks like, makes the first months on the medication much less confusing.

Wegovy is the brand name for semaglutide approved specifically for chronic weight management in adults (and some adolescents) with obesity or overweight plus a weight-related health condition. It is a once-weekly injection using a prefilled pen. It is worth noting that semaglutide is also sold under the brand name Ozempic for type 2 diabetes, at different approved doses. Wegovy and Ozempic share the same active ingredient, but they are approved for different indications and are not simply interchangeable versions of each other.

Why Wegovy Starts Low and Builds Up Gradually

Semaglutide works by mimicking a hormone called GLP-1 (glucagon-like peptide-1), which slows stomach emptying, reduces appetite, and affects how the brain regulates hunger and fullness. These effects are helpful for weight management, but they are also what cause the most common side effects of GLP-1 medications: nausea, vomiting, diarrhea, constipation, and stomach discomfort.

Starting at a very low dose and raising it gradually gives the digestive system time to adjust before the next increase. This does not eliminate side effects entirely, but it generally makes them more tolerable than jumping straight to a higher dose. The titration schedule is a core part of how Wegovy was studied and approved, not an optional add-on, so skipping steps or self-adjusting the schedule is not recommended without your prescriber's involvement.

The Wegovy Dose Escalation Schedule: Week by Week

The standard FDA-labeled titration schedule for Wegovy moves through five dose levels, each typically held for four weeks before the next increase:

- Weeks 1 through 4: 0.25 mg once weekly. This starting dose is not intended to produce significant weight loss on its own; its purpose is to let your body adjust.

- Weeks 5 through 8: 0.5 mg once weekly.

- Weeks 9 through 12: 1 mg once weekly.

- Weeks 13 through 16: 1.7 mg once weekly.

- Week 17 onward: 2.4 mg once weekly, which is the target maintenance dose used in most of the clinical trials that led to Wegovy's approval.

This adds up to about 16 to 17 weeks, roughly four months, to reach the full maintenance dose. Your prescriber may extend any step if you are having significant side effects, and the label allows for staying on the 1.7 mg dose as a maintenance dose for patients who cannot tolerate 2.4 mg. This is a legitimate, label-supported option, not a failure of treatment.

Each dose is given as a single subcutaneous (under-the-skin) injection, usually in the abdomen or thigh, once a week on the same day. It can be taken with or without food, and the injection site should be rotated to reduce irritation.

It is also worth setting expectations correctly: meaningful weight loss during the first one to two months, while you are still on low doses, is often limited. Most of the measurable effect builds once you reach and maintain the higher doses over several months, alongside nutrition and activity changes. A plateau in the first few weeks is expected, not a sign the medication isn't working.

Common Side Effects During Titration

Nausea is the most frequently reported side effect, especially in the first few weeks after each dose increase, followed by diarrhea, vomiting, constipation, and abdominal discomfort. These tend to be most noticeable right after a dose increase and often ease somewhat by the next cycle. Eating smaller, lower-fat meals, staying hydrated, and avoiding lying down right after eating can help with mild symptoms.

Some symptoms are not minor and warrant prompt medical attention rather than waiting for a scheduled follow-up. Contact your prescriber or seek urgent care for severe, persistent abdominal pain that may radiate to the back (a possible sign of pancreatitis), symptoms of a gallbladder problem such as right upper abdominal pain with fever or jaundice, signs of a serious allergic reaction such as facial or throat swelling or difficulty breathing, or signs of significant dehydration from ongoing vomiting or diarrhea. Semaglutide also carries a boxed warning regarding thyroid C-cell tumors seen in rodent studies; it is not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, which is why a thorough medical history is part of the evaluation before starting treatment.

What to Do About a Missed Dose or Side Effects You Can't Tolerate

If you miss a dose: According to Wegovy's labeling, if a dose is missed and it has been less than 5 days since the missed dose, take it as soon as you remember, then resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day; do not double up to make up for a missed dose. If you miss more than two doses in a row, contact your prescriber, since restarting at a lower dose may be recommended to avoid side effects from losing the gradual adjustment you had built up.

If side effects are hard to tolerate: Do not stop the medication abruptly or adjust your own dose without talking to your prescriber first. Common next steps include staying at your current dose for a longer period before advancing, temporarily dropping back to the previous dose, or in some cases remaining on a lower maintenance dose (such as 1.7 mg) rather than reaching 2.4 mg. Whether any of these is appropriate depends on your specific symptoms and medical history, which is why ongoing follow-up during titration matters rather than a one-time prescription handoff.

Who Should Not Use Wegovy, and What Alternatives Exist

Wegovy is not appropriate for everyone. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and it requires caution in people with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy. People on insulin or certain diabetes medications need coordinated monitoring because of hypoglycemia risk. These are reasons an individualized medical evaluation, not a generic checklist, should precede starting treatment.

For people who cannot use semaglutide or do not respond adequately to it, other options exist, including tirzepatide, a dual GIP/GLP-1 receptor agonist marketed as Zepbound for weight management, which works through a related but distinct mechanism. Nutrition changes, physical activity, and behavioral support remain part of any weight-management plan regardless of which medication, if any, is used, and some patients also explore non-invasive body contouring for localized concerns, which addresses appearance in treated areas rather than overall body weight or metabolic health.

The Bottom Line

Wegovy's dosing schedule is a deliberate, four-month ramp from 0.25 mg to a 2.4 mg maintenance dose, designed to reduce side effects while allowing the medication to reach an effective level. Side effects, especially gastrointestinal ones, are most common right after a dose increase and are a normal part of titration for many patients, though some symptoms need prompt medical attention rather than watching and waiting. Missed doses and intolerable side effects both have established, label-supported responses, but they should be handled in consultation with the prescriber managing your titration rather than decided on your own.

This article is for general education and does not replace an individualized evaluation. Whether Wegovy, a different GLP-1 medication, or another approach is appropriate for you depends on your medical history and should be determined with a qualified clinician.

If you are in the Laurel, Maryland area and are starting or considering GLP-1 therapy, Maryland Trim Clinic's GLP-1 weight-management program in Laurel, Maryland includes medical evaluation and follow-up as part of care. You can also review the clinic's broader medical weight loss program or contact the clinic to discuss your specific situation. Starting or continuing a GLP-1 medication should always involve an individualized evaluation rather than general information alone.

———

Frequently Asked Questions

Q: How long does it take to reach the full Wegovy dose?

A: Following the standard FDA-labeled titration schedule, it takes about 16 to 17 weeks, roughly four months, to move from the starting 0.25 mg dose to the 2.4 mg maintenance dose, with each step typically held for four weeks. Some patients take longer if a prescriber extends a step to manage side effects.

Q: Can I skip the titration steps and start at a higher dose to get results faster?

A: No. The gradual increase is part of how Wegovy was studied and approved, and it exists specifically to reduce gastrointestinal side effects like nausea and vomiting. Starting at or jumping to a higher dose without titrating increases the risk of significant side effects and is not recommended outside your prescriber's guidance.

Q: What should I do if I miss a Wegovy injection?

A: If it has been less than 5 days since the missed dose, take it as soon as you remember and continue your normal weekly schedule. If more than 5 days have passed, skip the missed dose and take the next one on your regular scheduled day; do not take two doses close together. If you miss more than two doses in a row, contact your prescriber, since you may need to restart at a lower dose.

Q: Is it normal to feel nauseous every time my dose increases?

A: Nausea and other digestive symptoms are common after a dose increase and often ease within that four-week period before the next step. If nausea is severe, persistent, or accompanied by significant abdominal pain, vomiting that prevents you from keeping fluids down, or signs of dehydration, contact your prescriber rather than waiting it out.

Q: Can I stay on a lower dose if 2.4 mg causes too many side effects?

A: Yes. Wegovy's labeling allows for 1.7 mg to be used as a maintenance dose for patients who do not tolerate the 2.4 mg target dose. This decision should be made with your prescriber based on how you are responding, rather than adjusted on your own.

Q: Is Wegovy the same medication as Ozempic?

A: They contain the same active ingredient, semaglutide, but they are different branded products approved for different uses and dosing. Ozempic is approved for type 2 diabetes management, while Wegovy is approved for chronic weight management, and the two should not be assumed to be interchangeable.